Pyxis Oncology (PYXS) completed sale of its rights to royalties from the commercialization of Enzeshu for a one-time cash payment of $11M. This non-dilutive funding will support the development of MICVO. As part of Pyxis Oncology’s acquisition of Apexigen, Inc. in August 2023, the Company acquired rights to royalties on Enzeshu and another asset discovered using APXiMAB, Apexigen’s proprietary antibody discovery platform. The Company’s current cash runway is expected to fund operations through data milestones and into the fourth quarter of 2026.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PYXS:
- Pyxis Oncology files $350M mixed securities shelf
- Pyxis Oncology price target raised to $8 from $5 at Stephens
- Pyxis Oncology Reports Increased Losses Amid Development Focus
- Promising Efficacy of Pyxis Oncology’s MICVO in HNSCC Justifies Buy Rating Despite Financial Constraints
- Buy Rating for Pyxis Oncology: Promising Clinical Data and Strong Financial Position